9 Beaten-Down Stocks That Look Promising

40
13
Favorite

9 Beaten-Down Stocks That Look Promising

Barrons2021-04-05

The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（13）

samfernando
·2021-04-05
Nice
Reply
Like
Report
EddyAng
·2021-04-05
Really?
Reply
2
Report
Fold Replies
- Big__Boss:
  nice
  2021-04-05
  Reply
  Report
- 我来啦你不要跑:
  Done
  2021-04-05
  Reply
  Report
iisterry
·2021-04-05
Most are still at a discount
Reply
1
Report
Maddy1234
·2021-04-05
Ok
Reply
Like
Report
jt1994
·2021-04-05
Wow
Reply
2
Report
Fold Replies
- Siewchin:
  Woaoaoa
  2021-04-05
  Reply
  Report
hisashi
·2021-04-05
Great
Reply
1
Report
Siewchin
·2021-04-05
Like and comment pls
Reply
4
Report
Fold Replies
- Qarah:
  Done
  2021-04-05
  Reply
  Report
jt1994
·2021-04-05
Wow
Reply
1
Report
Solsk
·2021-04-05
Woa
Reply
3
Report
SquareGuy
·2021-04-05
Citron beat down $nnox, time for it's real value
Reply
1
Report
Fold Replies
- Solsk:
  K
  2021-04-05
  Reply
  Report
Wryipqetuo
·2021-04-05
Like and comment please
Reply
4
Report
Fold Replies
- Siewchin:
  Hi
  2021-04-05
  Reply
  Report
- soooz:
  response plz
  2021-04-05
  Reply
  Report
3SPY
·2021-04-05
Like pls for coins, thank you
Reply
1
Report
Fold Replies
- Wryipqetuo:
  Like and comment on comment please
  2021-04-05
  Reply
  Report
- 3SPY:
  Ok
  2021-04-05
  Reply
  Report
gabrielteo
·2021-04-05
Let's see then..
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1186754751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-05 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186754751","market":"us","top_or_hot":-1,"title":"9 Beaten-Down Stocks That Look Promising","media":"Barrons","content":"<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Source Link</a>\n\n</div>\n","source":"lsy1601382232898","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DPZ","symbol_name":"达美乐比萨","start_time":0,"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","article_id":"1186754751","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","pubTimestamp":1617611806,"sourceInfo":{"source_id":"lsy1601382232898","name":"Barrons"},"weMediaInfo":null,"summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","collect":0,"end_time":0,"defaultTopTitle":"barrons.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DPZ":"达美乐比萨","DVA":"达维塔保健","ARTX":"阿罗特克","GPN":"环汇有限公司","CHTR":"特许通讯","QCOM":"高通","ALXN":"亚力兄制药","LDOS":"Leidos Holdings Inc"},"translate_title":"9只前景看好的重挫股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXN":0.9,"ARTX":0.9,"BLL":0.9,"CHTR":0.9,"DPZ":0.9,"DVA":0.9,"GPN":0.9,"LDOS":0.9,"QCOM":0.9},"content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":349262584,"gmtCreate":1617617174448,"gmtModify":1704700885712,"author":{"id":"3577774343761638","authorId":"3577774343761638","name":"samfernando","avatar":"https://static.tigerbbs.com/a0364524ada7527bd96fee8e8676450a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3577774343761638","idStr":"3577774343761638"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349262584","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349294910,"gmtCreate":1617613686930,"gmtModify":1704700835038,"author":{"id":"3573172201528943","authorId":"3573172201528943","name":"EddyAng","avatar":"https://static.tigerbbs.com/ff92cec8e8c5cef32f390c8687242f26","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3573172201528943","idStr":"3573172201528943"},"htmlText":"Really?&nbsp;","listText":"Really?&nbsp;","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/349294910","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961585,"gmtCreate":1617614780263,"gmtModify":1680782917311,"authorId":3570517865216539,"author":{"id":3570517865216539,"idStr":"3570517865216539","authorId":3570517865216539,"name":"Big__Boss","avatar":"https://static.tigerbbs.com/2c36c2fe68f671064d7d1fd9b7268165","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.03","exceedPercentage":"93.12%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349294910,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"},{"id":3961549,"gmtCreate":1617614382088,"gmtModify":1680782917197,"authorId":3546953115990917,"author":{"id":3546953115990917,"idStr":"3546953115990917","authorId":3546953115990917,"name":"我来啦你不要跑","avatar":"https://static.tigerbbs.com/5bd412726b1348c9275f5dcd38fff8a8","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.20","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349294910,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":349298246,"gmtCreate":1617613572185,"gmtModify":1704700829218,"author":{"id":"3574735608125569","authorId":"3574735608125569","name":"iisterry","avatar":"https://static.tigerbbs.com/d1e6ac22c3e636a9e4d60bfd6d96be2a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3574735608125569","idStr":"3574735608125569"},"htmlText":"Most are still at a discount","listText":"Most are still at a discount","text":"Most are still at a discount","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349298246","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349291262,"gmtCreate":1617613448356,"gmtModify":1704700827922,"author":{"id":"3574804387035345","authorId":"3574804387035345","name":"Maddy1234","avatar":"https://static.tigerbbs.com/1915c54767ae0efa98bc83dc26715dd9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574804387035345","idStr":"3574804387035345"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349291262","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349207089,"gmtCreate":1617612764841,"gmtModify":1704700821479,"author":{"id":"3580396500800332","authorId":"3580396500800332","name":"jt1994","avatar":"https://static.tigerbbs.com/256e9b9c026559d0a27973154fbb345d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3580396500800332","idStr":"3580396500800332"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/349207089","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961372,"gmtCreate":1617612823906,"gmtModify":1680782922027,"authorId":3579078250708703,"author":{"id":3579078250708703,"idStr":"3579078250708703","authorId":3579078250708703,"name":"Siewchin","avatar":"https://static.tigerbbs.com/70c1b2e3070d62cf13e834a0ac25c6f3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349207089,"type":1,"supId":0,"prevId":0,"content":"Woaoaoa","text":"Woaoaoa","html":"Woaoaoa"}],"langContent":"EN"},{"id":349204821,"gmtCreate":1617612702963,"gmtModify":1704700820020,"author":{"id":"3569379942872386","authorId":"3569379942872386","name":"hisashi","avatar":"https://static.tigerbbs.com/29366171e4326ad7326206178789c95f","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3569379942872386","idStr":"3569379942872386"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349204821","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349205862,"gmtCreate":1617612626756,"gmtModify":1704700819049,"author":{"id":"3579078250708703","authorId":"3579078250708703","name":"Siewchin","avatar":"https://static.tigerbbs.com/70c1b2e3070d62cf13e834a0ac25c6f3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3579078250708703","idStr":"3579078250708703"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/349205862","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961464,"gmtCreate":1617613757172,"gmtModify":1680782919824,"authorId":3570439473038184,"author":{"id":3570439473038184,"idStr":"3570439473038184","authorId":3570439473038184,"name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349205862,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":349202744,"gmtCreate":1617612602788,"gmtModify":1704700818561,"author":{"id":"3580396500800332","authorId":"3580396500800332","name":"jt1994","avatar":"https://static.tigerbbs.com/256e9b9c026559d0a27973154fbb345d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3580396500800332","idStr":"3580396500800332"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349202744","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349206780,"gmtCreate":1617612479240,"gmtModify":1704700817913,"author":{"id":"3574158219076158","authorId":"3574158219076158","name":"Solsk","avatar":"https://static.tigerbbs.com/1b2b1e76582f923826a2028b6b26521b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574158219076158","idStr":"3574158219076158"},"htmlText":"Woa","listText":"Woa","text":"Woa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349206780","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":349201585,"gmtCreate":1617612191947,"gmtModify":1704700813858,"author":{"id":"3561259559295872","authorId":"3561259559295872","name":"SquareGuy","avatar":"https://static.tigerbbs.com/c4aa86e9311a7ff0643a2e9f93645a8c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3561259559295872","idStr":"3561259559295872"},"htmlText":"Citron beat down $nnox, time for it's real value","listText":"Citron beat down $nnox, time for it's real value","text":"Citron beat down $nnox, time for it's real value","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/349201585","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961340,"gmtCreate":1617612489439,"gmtModify":1680782920266,"authorId":3574158219076158,"author":{"id":3574158219076158,"idStr":"3574158219076158","authorId":3574158219076158,"name":"Solsk","avatar":"https://static.tigerbbs.com/1b2b1e76582f923826a2028b6b26521b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349201585,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":349209458,"gmtCreate":1617611958574,"gmtModify":1704700811106,"author":{"id":"3554843666665701","authorId":"3554843666665701","name":"Wryipqetuo","avatar":"https://static.tigerbbs.com/3d7e355540fbe6cd2a446e3d745a2252","vip":1,"crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3554843666665701","idStr":"3554843666665701"},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/349209458","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961351,"gmtCreate":1617612640799,"gmtModify":1680782921588,"authorId":3579078250708703,"author":{"id":3579078250708703,"idStr":"3579078250708703","authorId":3579078250708703,"name":"Siewchin","avatar":"https://static.tigerbbs.com/70c1b2e3070d62cf13e834a0ac25c6f3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349209458,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"},{"id":3961306,"gmtCreate":1617612099298,"gmtModify":1663225046827,"authorId":3573366788945030,"author":{"id":3573366788945030,"idStr":"3573366788945030","authorId":3573366788945030,"name":"soooz","avatar":"https://static.tigerbbs.com/8d877c5bd7fb60b3566a2e006810af97","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.87%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349209458,"type":1,"supId":0,"prevId":0,"content":"response plz","text":"response plz","html":"response plz"}],"langContent":"EN"},{"id":349209207,"gmtCreate":1617611943309,"gmtModify":1704700810945,"author":{"id":"3573557817579971","authorId":"3573557817579971","name":"3SPY","avatar":"https://static.tigerbbs.com/d0da4d80440800d9415c7b37917c8288","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573557817579971","idStr":"3573557817579971"},"htmlText":"Like pls for coins, thank you&nbsp;","listText":"Like pls for coins, thank you&nbsp;","text":"Like pls for coins, thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/349209207","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3961289,"gmtCreate":1617611970930,"gmtModify":1680782921632,"authorId":3554843666665701,"author":{"id":3554843666665701,"idStr":"3554843666665701","authorId":3554843666665701,"name":"Wryipqetuo","avatar":"https://static.tigerbbs.com/3d7e355540fbe6cd2a446e3d745a2252","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349209207,"type":1,"supId":0,"prevId":0,"content":"Like and comment on comment please","text":"Like and comment on comment please","html":"Like and comment on comment please"},{"id":3961303,"gmtCreate":1617612067958,"gmtModify":1680782919855,"authorId":3573557817579971,"author":{"id":3573557817579971,"idStr":"3573557817579971","authorId":3573557817579971,"name":"3SPY","avatar":"https://static.tigerbbs.com/d0da4d80440800d9415c7b37917c8288","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":349209207,"type":1,"supId":3961289,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":349200482,"gmtCreate":1617611880646,"gmtModify":1704700809320,"author":{"id":"3574382626951879","authorId":"3574382626951879","name":"gabrielteo","avatar":"https://static.tigerbbs.com/adbaa4aaf497e6523199049f0ad42d1c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574382626951879","idStr":"3574382626951879"},"htmlText":"Let's see then..&nbsp;","listText":"Let's see then..&nbsp;","text":"Let's see then..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/349200482","repostId":1186754751,"repostType":4,"repost":{"id":"1186754751","pubTimestamp":1617611806,"share":"https://ttm.financial/m/news/1186754751?lang=&edition=fundamental","pubTime":"2021-04-05 16:36","market":"us","language":"en","title":"9 Beaten-Down Stocks That Look Promising","url":"https://stock-news.laohu8.com/highlight/detail?id=1186754751","media":"Barrons","summary":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every sto","content":"<p>The S&amp;P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.</p><p>While the majority of S&amp;P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.</p><p>Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.</p><p>Among the nearly 100 S&amp;P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.</p><p>To find stocks whose earnings potential may not be reflected in share prices,<i>Barron’s</i>took those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.</p><p>Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.</p><p><b>Left Behind</b></p><p>These fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.</p><p><img src=\"https://static.tigerbbs.com/354b69e346e0d3878e95ee2a83301ccf\" tg-width=\"939\" tg-height=\"781\" referrerpolicy=\"no-referrer\"></p><p>Chip maker&nbsp;Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but&nbsp;still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could&nbsp;benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.</p><p>Vertex Pharmaceuticals&nbsp;(VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,<i>Barron’s</i>&nbsp;wrote in March that&nbsp;Vertex remains a powerhouse in cystic fibrosis treatment&nbsp;and is developing a promising pipeline beyond that.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Beaten-Down Stocks That Look Promising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Beaten-Down Stocks That Look Promising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-05 16:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for ...</p>\n\n<a href=\"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LDOS":"Leidos Holdings Inc","QCOM":"高通","CHTR":"特许通讯","ARTX":"阿罗特克","DPZ":"达美乐比萨","DVA":"达维塔保健","GPN":"环汇有限公司","ALXN":"亚力兄制药"},"source_url":"https://www.barrons.com/articles/9-beaten-down-stocks-that-look-promising-51617404656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186754751","content_text":"The S&P 500 closed at a record on Thursday, soaring above 4000 for the first time. But not every stock has shared in those gains so far this year.While the majority of S&P 500 stocks are positive for the year, about one in five have declined in the first quarter of 2021. Some are down for fundamental reasons, while others seem to be suffering from the market’s momentum shift from growth stocks to cyclical and value names.Once the headwind wanes, however, names that have been left behind are likely to catch up as their earnings estimates remain strong. In some cases, analysts have adjusted their expectations higher this year. That presents a good opportunity to snap up shares of fundamentally solid companies at discount prices.Among the nearly 100 S&P 500 companies whose shares are in negative territory year to date, about half are expected to post 2021 earnings per share that are at least 20% higher than fiscal 2019 earnings. Among those, about 30 are expected to see that strength sustain into 2022, meaning their 2022 earnings are expected to grow at least another 10% from 2021 levels.To find stocks whose earnings potential may not be reflected in share prices,Barron’stook those 30 names and removed any stocks that traded at more than 30 times 2021 earnings estimates. That left us with nine names.Even better, analysts have raised their 2021 and 2022 earnings estimates for all of the stocks since the end of last year, meaning Wall Street is turning more bullish on them. These discounted names are mostly growth stocks across healthcare, tech, telecommunication, and consumer sectors.Left BehindThese fundamentally solid stocks are in negative territory for 2021 but look well-positioned to catch up.Chip maker Qualcomm(ticker: QCOM), for example, has seen its stock tumble nearly 10% year to date. Investors appear unimpressed by the company’s first-quarter revenue, which was 62% higher than a year ago but still missed analysts’ expectations. In the longer term, the company–known for chips that power smartphone processors–could benefit from the world’s transition to 5G networksand the Biden administration’s proposed infrastructure spending.Vertex Pharmaceuticals (VTRX) shares are another example where a recent pullback due to negative events may have gone too far. In mid-October, the biotech company canceled the development of a once-promising drug after trial results disappointed. Its stock has plunged 23% since and is down 10% year to date. Despite the flop of that one drug,Barron’s wrote in March that Vertex remains a powerhouse in cystic fibrosis treatment and is developing a promising pipeline beyond that.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":40,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}